Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Disease
- Biotechnology
- Alzheimer’s disease
- Parkinsons Disease
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3433
License Grant
As a result of a merger, the Licensee obtained exclusive, worldwide rights to a delayed-release cysteamine bitartrate (DR Cysteamine) currently in a Phase II clinical trial for treatment for patients with Huntington’s Disease from the University. Previous research has indicated that DR Cysteamine can prevent abnormal neuronal cell death caused by Huntington’s. Preclinical studies demonstrated in 2006 prevention of neuronal apoptosis through usage of cysteamine. Treatment with cysteamine is linked to increased levels of Brain derived neurotrophic factor (BDNF) which protects brain cells and promotes growth of new brain cells. Their study showed an increase in both brain and blood levels of BDNF, which allows this protein to be used as a biomarker.
Field of Use
The rights granted apply to the healthcare industry. BDNF is known to be depressed in patients with Huntington’s. If proven efficacious and viable, treatment with DR Cysteamine could protect from the neuronal cell death by increasing levels of protective BDNF.
IPSCIO Record ID: 29256
License Grant
As a result of a merger, the Licensee received the exclusive worldwide License to DR Cysteamine, a proprietary enterically coated formulation of cysteamine bitartrate, a cystine depleting agent currently approved by the FDA for nephropathic cystinosis. Cysteamine bitartrate is prescribed for the management of the genetic disorder known as cystinosis, is sold as a non-enterically coated capsule as CystagonTM by Mylan Laboratories.
License Property
DR Cysteamine is a proprietary enterically coated formulation of cysteamine bitartrate, a cystine depleting agent currently approved by the FDA for nephropathic cystinosis.
Field of Use
Cysteamine bitartrate is prescribed for the management of the genetic disorder known as cystinosis, is sold as a non-enterically coated capsule as CystagonTM by Mylan Laboratories. Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of the amino acid cystine.
IPSCIO Record ID: 117984
License Grant
Licensor grants to the German Licensee an exclusive worldwide license and / or sublicense, with a right to sublicense, under the Patents, the Know-How and the Joint Patents to use, develop, manufacture, have manufactured, market, sell, import for sale and distribute the Compound and / or the Product in the Territory for use in the Field. Licensor will grant additional sublicenses to third parties designated by Licensee.
License Property
Licensor is developing through its research and development activities a compound consisting of human retinal pigment epithelial cells on microcarriers for use, inter alia, in the treatment of Parkinsons Disease and Parkinsonian Movement Disorders.
Field of Use
Initial Indication is for the use of Product for the in vivo therapeutic prevention, treatment, cure or mitigation of Parkinsons Disease and / or Parkinsonian Movement Disorders.
IPSCIO Record ID: 3499
License Grant
A Swiss licensee and an Irish licensor announced a worldwide, exclusive collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002. The license is granting rights to develop, make, have made, use, sell, offer to sell, import, and export the Licensed Products. Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.
Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.
License Property
PRX002 is a monoclonal antibody for the treatment of Parkinsons disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinsons disease in 2014.
Synuclein proteins are a family of charged proteins found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies.
Field of Use
The rights granted apply to the medical industry. Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.
IPSCIO Record ID: 1268
License Grant
The Licensor today announced that the Company and the Licensee have mutually agreed to modify their collaboration Agreement for the development and commercialization of ELND005.
License Property
Based on studies in preclinical models of Alzheimer’s disease, ELND005 is believed to inhibit the aggregation (clumping) of amyloid-beta proteins in the brain thereby neutralizing the toxic effects of these aggregates on nerve cell membranes (synapses). The toxic effects of amyloid-beta proteins include inhibition of nerve cell function and eventually death of nerve cells (neurons), resulting in memory loss and ultimately the dementia that is characteristic of Alzheimer’s disease (AD). The safety and pharmacokinetics of ELND005 were evaluated in a total of 9 Phase 1 studies in 161 healthy volunteers, including healthy elderly subjects. ELND005 has also been evaluated in a completed Phase 2 study in mild to moderate Alzheimer’s patients and an open-label extension of this Phase 2 study is currently ongoing.
ELND005 received fast track designation from the U.S. Food and Drug Administration (FDA) in 2007 for treatment of Alzheimer’s disease. Fast track designation can facilitate development and may expedite regulatory review of drugs that the FDA recognizes as potentially addressing an unmet medical need for serious or life-threatening conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
